<DOC>
	<DOCNO>NCT01190254</DOCNO>
	<brief_summary>This study design evaluate whether asenapine , approve United States Food Drug Administration ( US FDA ) acute treatment schizophrenia adult , also effective adolescent schizophrenia . Participants qualify study randomly assign receive fix dose asenapine ( either 2.5 mg 5 mg twice daily [ BID ] ) placebo 8 week . Throughout study , observation make participant various time assess efficacy safety study treatment . The primary objective trial demonstrate significant superiority least one asenapine dose placebo , measure change baseline Positive Negative Syndrome Scale ( PANSS ) total score Day 56 .</brief_summary>
	<brief_title>Fixed Dose Efficacy Safety Study Asenapine Treatment Schizophrenia Adolescents ( P05896 )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Schizophrenia , Disorganized</mesh_term>
	<mesh_term>Schizophrenia , Paranoid</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<criteria>Each participant must schizophrenia , diagnose confirm boardeligible board certify psychiatrist least two year specialization pediatric/adolescent psychiatric medicine . Each participant must ≥12 year age &lt; 18 year age . Each participant must minimum PANSS total score 80 Screening Baseline . Each participant must score least 4 ( moderate ) two five item positive subscale PANSS ( delusion , conceptual disorganization , hallucinatory behavior , grandiosity , suspiciousness/ persecution ) Screening Baseline . Each participant must CGIS scale score ≥4 Screening Baseline . Each participant must taper prohibit psychotropic medication ( include antipsychotic , antidepressant , mood stabilizer ) prior Baseline . Each participant must agree begin formal , structure psychotherapy trial . A participant must diagnosis schizoaffective disorder ; schizophrenia residual subtype ; schizophrenia catatonic subtype , schizophrenia `` continuous , '' `` single episode partial remission , '' `` single episode full remission '' course specifier . A participant must primary Axis I diagnosis schizophrenia must comorbid Axis I diagnosis primarily responsible current symptom functional impairment . A participant must know suspected diagnosis mental retardation organic brain disorder . A participant must currently ( within past 6 month ) meet Diagnostic Statistical Manual Mental DisordersIVText Revision ( DSMIVTR^TM ) criterion substance abuse dependence ( exclude nicotine ) . A participant must diagnosis psychotic disorder behavioral disturbance think substance induce due substance abuse . A participant must imminent risk selfharm harm others , investigator 's opinion base clinical interview response provide Columbia Suicide Severity Rating Scale ( CSSRS ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Asenapine</keyword>
	<keyword>adolescent</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>phase IIIb</keyword>
	<keyword>placebo-controlled</keyword>
</DOC>